Researcher Spotlight: Professor Kamal (Kam) Dua

Earlier this year NICM was proud to welcome Prof Kamal (Kam) Dua to our institute and WSU’s School of Science as Professor of Pharmaceutical Sciences.

In this Researcher Showcase, he shares insights into his team’s key priorities and his vision for advancing evidence-based, integrative health research.

What major health challenges is your research focused on solving?

My research is focused on addressing major unmet health challenges associated with inflammatory diseases, with particular emphasis on chronic lung disorders that significantly contribute to global morbidity and healthcare burden. These conditions often suffer from limited therapeutic efficacy, poor targeting, and suboptimal patient outcomes.

Leveraging my multidisciplinary expertise in drug delivery systems, biomedical sciences, immunology, and microbiology, I aim to bridge the gap between biological discovery and clinical translation.

My work involves identifying critical molecular and immunological targets that regulate disease pathophysiology and engineering advanced, targeted drug delivery platforms to enhance therapeutic precision, efficacy, and safety. By integrating formulation science with disease biology, my research seeks to overcome key limitations of conventional therapies and enable more effective, patient-centric treatment strategies.

In parallel, I am addressing emerging global health and wellness challenges by developing innovative delivery systems for bioactive compounds derived from medicinal plants. This research supports the advancement of phytoceuticals, nutraceuticals, and functional foods, offering sustainable, preventive, and complementary therapeutic solutions aligned with the growing demand for natural and integrative healthcare approaches.

Overall, my research vision is driven by the goal of creating clinically translatable, scalable, and globally relevant solutions that improve healthcare outcomes. Through impactful scientific contributions and cross-disciplinary leadership, I aim to strengthen national and international research capacity while aligning my work with the United Nations Sustainable Development Goals, particularly those focused on good health, well-being, and sustainable innovation.

You joined the Institute early in 2026, what brought you to NICM?

The opportunity to contribute to and grow within a world-leading centre of integrative and evidence-based health research that bridges conventional biomedical science with complementary medicine.

I am particularly inspired by NICM’s multidisciplinary approach, spanning clinical trials, laboratory research, policy engagement, and translational science, which aligns seamlessly with my own research vision of moving discoveries from bench to bedside.

The Institute’s focus on pressing health priorities, including immunity and inflammation, cardiovascular and metabolic health, neurocognitive and mental health, reproductive health, and cancer recovery, resonates strongly with my work on inflammatory diseases and advanced drug delivery systems.

Moreover, NICM’s commitment to rigorous evidence generation and integrative healthcare solutions offers an exciting platform to expand my research into natural bioactive compounds and innovative therapeutics within a globally respected institute. Being part of a vibrant research community, which includes world-class scientists, clinicians and students, will not only enhance my interdisciplinary collaborations but also amplify the real-world impact of our collective scientific contributions.

Ultimately, joining NICM represented an unparalleled opportunity to pursue research that is both scientifically rigorous and socially meaningful, contributing to improved health outcomes and advancing the field of integrative medicine on a global scale.

What are the key focus areas for you and your research team at the moment?

This year, the key focus for my research team is addressing inflammation-driven diseases arising from escalating environmental and occupational exposures, especially lung diseases, which represent a growing and urgent public health challenge in Australia and globally. Specifically, we aim to investigate the pathophysiological consequences of emerging environmental insults, including air pollution, bushfire smoke, silicosis-related particulates, and microplastics, etc., which disproportionately affect respiratory, immune, and systemic health.

Our research concentrates on elucidating the molecular and immunological mechanisms underlying exposure-induced inflammation and tissue damage, with a particular emphasis on lung and immune health. Building on these insights, we’re aiming to develop and optimise next-generation drug and nutraceutical delivery systems that encapsulate carefully selected phytoceuticals and natural bioactives to enhance their stability, bioavailability, and targeted therapeutic action.

From a national perspective, this work directly aligns with Australian health priorities, particularly in mitigating the long-term health impacts of bushfires, environmental pollution, and occupational lung diseases, issues of increasing relevance in the context of climate change and industrial exposure. Internationally, our research addresses globally shared environmental health challenges, positioning our outcomes for broad translational relevance across diverse populations and healthcare systems.

Ultimately, our goal is to deliver clinically translatable, scalable, and sustainable interventions that reduce inflammation-driven disease burden, support preventive health strategies, and contribute to evidence-based integrative healthcare solutions. Through strong national and international collaborations, we aim to ensure that our research delivers measurable health, economic, and societal impact.